The Roche Holding AG stock has been in the spotlight due to various happenings. Despite facing challenges including Trump’s drug pricing order, healthcare stocks including Roche are listed as best to buy. Its momentum as a great stock is matched by its aggressive acquisition strategies, notably the $1.5 billion acquisition of U.S. bio-pharma company, Poseida. This is alongside a $5.3 billion obesity drug deal with Zealand Pharma that marked 'The Largest Obesity Deal To Date'. The signing of such a monumental deal was followed by a spike in Roche shares. However, the journey wasn't entirely smooth as some headlines hint at stock declines due to challenges such as competition and issues in drug trials.
A significant development for Roche was CHMP's approval of Itovebi Combo for Breast Cancer in the EU. Despite a 21% loss endured by shareholders in the last three years, Roche continues to promise high single-digit core profit growth by 2025. Additionally, Roche is showing strong commitment by investing hugely in its Pharma and Diagnostics sectors in the US. The company is also making strides in developing new treatments from Alzheimer's to liver diseases. However, concerns regarding its obesity drug side effects and failure in its new high-dose version of its top-selling drug study caused some turbulence in its stock journey.
Roche Stocks News Analytics from Thu, 12 Sep 2024 07:00:00 GMT to Mon, 30 Jun 2025 05:26:23 GMT - Rating 6 - Innovation -3 - Information 3 - Rumor -7
